Capital International Inc. CA Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Capital International Inc. CA increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 193.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,493 shares of the biotechnology company’s stock after buying an additional 14,822 shares during the quarter. Capital International Inc. CA’s holdings in Sarepta Therapeutics were worth $2,735,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Manchester Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in Sarepta Therapeutics during the 4th quarter worth $36,000. Steward Partners Investment Advisory LLC grew its position in Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in Sarepta Therapeutics by 95.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 216 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $53.79 on Monday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a market cap of $5.22 billion, a PE ratio of 43.03 and a beta of 0.93. Sarepta Therapeutics, Inc. has a one year low of $48.01 and a one year high of $173.25. The business’s fifty day moving average price is $82.21 and its two-hundred day moving average price is $107.70.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SRPT. Royal Bank of Canada cut Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Deutsche Bank Aktiengesellschaft cut their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research note on Wednesday, March 19th. HC Wainwright reiterated a “neutral” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Wells Fargo & Company started coverage on shares of Sarepta Therapeutics in a research note on Friday, April 11th. They issued an “overweight” rating and a $115.00 price objective on the stock. Finally, Scotiabank reduced their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $161.83.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.